Using blood tests to analyze tumor DNA in breast and digestive cancers
Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer
This study is testing whether blood tests that look for tumor DNA can help improve treatment and monitoring for people with breast, digestive, and gynecologic cancers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poitiers University Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Poitiers) |
| Trial ID | NCT04530890 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of circulating tumor DNA (ctDNA) obtained from blood samples to improve the management of patients with breast, digestive, and gynecologic cancers. By employing advanced molecular biology techniques like Next Generation Sequencing (NGS), the study aims to assess the diagnostic, prognostic, and predictive capabilities of ctDNA in response to oncological treatments. Additionally, the study explores the potential of exosomes as future biomarkers in cancer management. The research focuses on patients requiring chemotherapy or immunotherapy, providing a non-invasive method to monitor tumor characteristics.
Who should consider this trial
Good fit: Ideal candidates include adults with proven or suspected digestive or gynecological/breast cancer who require oncological treatment.
Not a fit: Patients with a history of other cancers within the past five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for cancer patients.
How similar studies have performed: Other studies have shown promise in using ctDNA for cancer management, indicating a growing interest and potential in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Digestive or gynecological / breast cancer proven or suspected, requiring oncological treatment (chemotherapy or immunotherapy) * Major patient * Patients benefiting from a Social Security scheme or benefiting through the intermediary of a third party * Information note and collection of non-opposition after clear and fair information about the study Exclusion Criteria: * Linguistic or psychological refusal or inability to understand and / or sign the information and no-objection note * History of a cancer other than that allowing inclusion in the 5 years preceding inclusion
Where this trial is running
Poitiers
- CHU POitiers — Poitiers, France (Recruiting)
Study contacts
- Study coordinator: Camille EVRARD, PHD
- Email: camille.evrard@chu-poitiers.fr
- Phone: +33549444279
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.